PROGNOSTIC FACTORS FOR RESPONSE AND SURVIVAL WITH ALPHA-INTERFERON (IFN-A) THERAPY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML)

被引：0
|
作者：
KANTARJIAN, H [1 ]
SMITH, T [1 ]
OBRIEN, S [1 ]
ROBERTSON, L [1 ]
KOLLER, C [1 ]
BERAN, M [1 ]
KEATING, M [1 ]
TALPAZ, M [1 ]
机构：
[1] MD ANDERSON CANC CTR,HOUSTON,TX
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A378 / A378
页数：1
相关论文
共 50 条
  • [11] IMMUNE-MEDIATED AND UNUSUAL COMPLICATIONS DURING ALPHA-INTERFERON THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
    SACCHI, S
    KANTARJIAN, H
    COHEN, P
    PIERCE, S
    TALPAZ, M
    BLOOD, 1994, 84 (10) : A150 - A150
  • [12] CHRONIC MYELOGENOUS LEUKEMIA - HEMATOLOGICAL REMISSIONS WITH ALPHA-INTERFERON
    TALPAZ, M
    MCCREDIE, K
    KANTARJIAN, H
    TRUJILLO, J
    KEATING, M
    GUTTERMAN, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (01) : 87 - 95
  • [13] Cost-effectiveness of alpha-interferon (IFN) treatment in chronic myeloid leukemia (CML)
    Liberato, NL
    Quaglini, S
    Barosi, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 272 - 272
  • [14] Treatment of Philadelphia chromosome (Ph)-positive early chronic phase (CP) chronic myelogenous leukemia (CML) with daily doses of interferon alpha (IFN-A) and low dose cytosine arabinoside (ara-C).
    Kantarjian, HM
    O'Brien, S
    Rios, MB
    Cortes, J
    Giles, FJ
    Andreeff, M
    Keating, MJ
    Talpaz, M
    BLOOD, 1998, 92 (10) : 246B - 246B
  • [15] Suppression of clonal evolution in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on interferon alfa therapy (IFN-A) therapy.
    Cortes, J
    Kantarjian, H
    OBrien, S
    Beran, M
    Estey, E
    Koller, C
    Andreeff, M
    Kornblau, S
    Keating, M
    Freireich, EJ
    Talpaz, M
    BLOOD, 1996, 88 (10) : 918 - 918
  • [16] Effect of interferon-alpha (IFN-A) on different lymphocyte subpopulations in patients with chronic myeloid leukemia (CML).
    Cortes, J
    Sacchi, S
    Kantarjian, H
    Talpaz, M
    BLOOD, 1996, 88 (10) : 3514 - 3514
  • [17] Interferon alpha (IFN-A) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, H
    OBrien, S
    Beran, M
    Koller, C
    Andreeff, M
    Rios, MB
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1995, 86 (10) : 2105 - 2105
  • [18] CLINICAL AND CYTOLOGIC CHARACTERISTICS OF BLASTIC PHASE (BP) IN PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) TREATED WITH ALPHA-INTERFERON
    ALIMENA, G
    MORRA, E
    LAZZARINO, M
    MANCINI, M
    CEDRONE, M
    MONTEFUSCO, E
    MERANTE, S
    RONDINELLI, MB
    BERNASCONI, P
    MELONI, G
    BERNASCONI, C
    MANDELLI, F
    BLOOD, 1994, 84 (10) : A629 - A629
  • [19] DOSE RELATED EFFECTIVENESS OF ALPHA-INTERFERON IN CHRONIC MYELOGENOUS LEUKEMIA
    GASTL, G
    AULITZKY, Q
    TILG, H
    HUBER, H
    HAUSMANINGER, H
    SEEWANN, HL
    COSER, C
    PRINOTH, P
    HUBER, C
    BLUT, 1987, 54 (04): : 251 - 252
  • [20] Association of hla phenotype and response to interferon alfa (IFN) in patients with chronic myelogenous leukemia (CML).
    Cortes, J
    Kantarjian, H
    Talpaz, M
    BLOOD, 1995, 86 (10) : 1739 - 1739
12345